ReviewNature protocols2026
Branching beyond bifunctional linkers: synthesis of macrocyclic and trivalent PROTACs.
Review in Nature protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research progress and future perspectives in proteolysis-targeting chimeras.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proteolysis-targeting chimeras (PROTACs) are traditionally conceptualized and synthesized by connecting two ligands, one for a target protein and one for an E3 ligase, via a bifunctional linker. Chemical creativity has recently explored the development of more elaborate and unusual linkers beyond conventional bifunctionals, allowing the development of macrocyclic and trivalent PROTACs. In two distinct proof-of-concept studies guided by the co-crystal structure of bivalent PROTAC MZ1 in complex with the E3 ubiquitin ligase von Hippel-Lindau and the second bromodomain of Brd4, we designed macrocyclic macroPROTAC-1 and trivalent PROTAC SIM1. These designs aimed to enhance protein degradation by constraining the PROTAC in its bioactive conformation or increasing avidity and cooperativity within the PROTAC ternary complex by augmenting the binding valency to the target protein, respectively. Here we describe the step-by-step synthesis of the macrocyclic macroPROTAC-1 and trivalent PROTAC SIM1, detailing the generation of the macrocyclic and trivalent cores and their subsequent conjugation to the respective ligands. This two-part procedure is expected to take ~14 d for the synthesis of macroPROTAC-1 and 10 d for the synthesis of SIM1. In this protocol, we also provide a brief introduction into the biophysical and cellular evaluation of these unusual molecules, representative structures of key negative control compounds and their utility, and highlight recent developments and expansion beyond pioneering exemplars.
Indexed as
Identifiers
41219525What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.